Skip to main content
  • Submit
  • About
    • Editorial Board
    • PNAS Staff
    • FAQ
    • Accessibility Statement
    • Rights and Permissions
    • Site Map
  • Contact
  • Journal Club
  • Subscribe
    • Subscription Rates
    • Subscriptions FAQ
    • Open Access
    • Recommend PNAS to Your Librarian
  • Log in
  • My Cart

Main menu

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
  • About
    • Editorial Board
    • PNAS Staff
    • FAQ
    • Accessibility Statement
    • Rights and Permissions
    • Site Map
  • Contact
  • Journal Club
  • Subscribe
    • Subscription Rates
    • Subscriptions FAQ
    • Open Access
    • Recommend PNAS to Your Librarian

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Home
Home

Advanced Search

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses

New Research In

Physical Sciences

Featured Portals

  • Physics
  • Chemistry
  • Sustainability Science

Articles by Topic

  • Applied Mathematics
  • Applied Physical Sciences
  • Astronomy
  • Computer Sciences
  • Earth, Atmospheric, and Planetary Sciences
  • Engineering
  • Environmental Sciences
  • Mathematics
  • Statistics

Social Sciences

Featured Portals

  • Anthropology
  • Sustainability Science

Articles by Topic

  • Economic Sciences
  • Environmental Sciences
  • Political Sciences
  • Psychological and Cognitive Sciences
  • Social Sciences

Biological Sciences

Featured Portals

  • Sustainability Science

Articles by Topic

  • Agricultural Sciences
  • Anthropology
  • Applied Biological Sciences
  • Biochemistry
  • Biophysics and Computational Biology
  • Cell Biology
  • Developmental Biology
  • Ecology
  • Environmental Sciences
  • Evolution
  • Genetics
  • Immunology and Inflammation
  • Medical Sciences
  • Microbiology
  • Neuroscience
  • Pharmacology
  • Physiology
  • Plant Biology
  • Population Biology
  • Psychological and Cognitive Sciences
  • Sustainability Science
  • Systems Biology
Commentary

Myriad of implications of acetyl-l-carnitine deficits in depression

Robert M. Post
PNAS August 21, 2018 115 (34) 8475-8477; first published August 1, 2018; https://doi.org/10.1073/pnas.1811389115
Robert M. Post
aDepartment of Psychiatry and Behavioral Sciences, George Washington University School of Medicine, Washington, DC 20037;
bBipolar Collaborative Network, Bethesda, MD 20814
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: robert.post@speakeasy.net

See related content:

  • Acetyl-l-carnitine deficiency in patients with major depressive disorder
    - Jul 30, 2018
  • Article
  • Figures & SI
  • Info & Metrics
  • PDF
Loading

The report of Nasca et al. (1) of low levels of acetyl-l-carnitine (LAC) in depression promises to have a major impact in the understanding and treatment of major depression. It may also have implications for other types of depressive illnesses such as bipolar disorder and even posttraumatic stress disorder (PTSD).

The findings are especially noteworthy from a number of different perspectives. They are from two different study populations, and the values are documented by two different assays. LAC levels were not only lower in depressed patients in general but lower in those with greater illness severity as well as an earlier age of onset, the latter of which is a risk factor for a poor outcome in adulthood. In those with a history of treatment-resistant depression (TRD), LAC was lower in females and those experiencing emotional neglect.

The convergence of these clinical findings with those in animal models of depression makes the potential implications even more striking. Low levels of LAC are found in several different models, and impressively, treatment of these animals with LAC resulted in rapid onset of improvement in their depressive-like behaviors. In an earlier paper in PNAS, Nasca et al. (2) reported that these effects of LAC were conveyed by an epigenetic mechanism involving rapid up-regulation of type 2 metabotropic glutamate (mGlu2) receptors, which are inhibitory to glutamate release. This occurred by increasing levels of acetylated H3K27 bound to the Grm2 promoter, yielding increased transcription of Grm2 in hippocampus and prefrontal cortex. The rapid increase in mGlu2 receptors was associated with improvement in depressive-like behaviors in 3 d as opposed to the usual 14 d of treatment required with the traditional tricyclic antidepressant (AD) clomipramine. The LAC also was associated with increases in BDNF and acetylation of NF-ĸB p65 subunit and improved insulin resistance.

Nasca et al. (1) were appropriately conservative in interpreting their findings and pointing out multiple directions for future studies. However, a commentator is not bound by such restrictions, and I will note a variety of potential implications that open new avenues for therapeutics and theoretical formulations. Nasca et al. (1) point out the need to further validate their findings and the association with treatment-refractory females with a history of early adversity. Most importantly, well-controlled clinical therapeutic studies of LAC in depression and TRD and its correlates would be an excellent first step. In addition, assessment of LAC levels in patients with bipolar disorder could be of considerable import, especially since childhood adversity is a risk factor for early-onset bipolar disorder and a more difficult and treatment-resistant subsequent course of illness (3).

It should be pointed out that among the preliminary clinical studies and reviews of LAC that Nasca et al. (1) cited was the suggestion of better tolerability of LAC compared with other ADs, and a more rapid onset of effect compared with fluoxetine in dysthymic elderly patients (4). Thus, it is possible that, as with findings in the preclinical models, LAC will exert rapid-acting AD effects clinically. This is noteworthy as several other rapid-acting ADs, such as ketamine, have effects in modulating glutamate (blocking NMDA receptors and increasing AMPA receptors) and increasing BDNF. Interestingly, lamotrigine, as well as carbamazepine, decrease glutamate release and also appear to have AD effects but of the slower-onset variety, nonetheless further suggesting that decreasing excess synaptic glutamate is associated with AD effects (5⇓–7). N-Acetylcysteine, which has a slow onset of AD effects (8), increases glutamate transporters, clearing glutamate into glial cells (6, 7, 9). Thus, LAC may take its place among the three other AD modalities that decrease synaptic glutamate, but doing this in a unique way based on rapid-onset epigenetic effects on increasing the transcription of inhibitory metabotropic mGluR2 receptors.

The decreases in LAC induced in animals are of particular interest, as chronic, uncontrollable, and defeat stress are also considered models for PTSD. Childhood trauma has pleomorphic effects in increasing incidence or early age of onset of multiple psychiatric and medical disorders (10, 11). If LAC decreases in humans are similarly related to childhood adversity, one could consider the possibility that treatment with LAC could have wide-ranging effects in preventing or reversing vulnerability to many illnesses.

Considerable evidence indicates that early stress can leave a vulnerability memory trace that predisposes to the development in adulthood of depression, bipolar disorder, and PTSD (6, 12⇓–14) (Fig. 1). This memory engram appears based on epigenetic marks left on histones, DNA, and mRNA that convey sensitization (increased reactivity) to the recurrence not only of stressors but also mood episodes and bouts of substance abuse (13). There also appears to be cross-sensitization among these three types of increased reactivities, which further drive illness progression (7, 13, 15, 16). In addition, in the recurrent mood disorders, after the appearance of enough stress-induced episodes, depressions can also begin to emerge in the absence of precipitating stressors, following a kindling-like progression to spontaneous episodes (12, 13). Early-onset bipolar disorder is more prevalent in the United States compared with many European countries and runs a more difficult course, as those in the United States have more genetic vulnerability, childhood stress, affective episodes and rapid cycling, and substance abuse (3), such that earlier and new treatment interventions are desperately needed.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Depression as a progressive illness. When do low levels of acetyl-l-carnitine emerge in the evolution of depression?

That LAC treatment might reverse some of the epigenetic-based vulnerability could have enormous clinical implications. In the defeat-stress model, the low BDNF in the hippocampus is related to trimethylation of H3K27 (H3K27me3) that is not reversed by traditional ADs (even though they do reverse the BDNF changes and the behavioral deficits) (17, 18). Since LAC increases acetylation of H3K27, it raises the possibility of more permanent elimination of vulnerability to defeat-stress depression-like behaviors. This proposition could readily be tested in animals and pursued clinically.

To the extent that some vulnerability to depression is based on these early childhood experiences, LAC treatment could theoretically reverse that vulnerability in the long term in a fashion different from traditional ADs, which require continued prophylactic treatment to prevent recurrent depressions (6, 14). This clinical possibility is further bolstered by the findings that LAC can induce resilience in an animal model by increasing astroglial cysteine-glutamate exchangers and glutamate transporters in the ventral hippocampus (9). LAC can also increase the structural plasticity in the medial amygdala and reverse depressive-like behaviors in a chronic restraint-stress model (19). It also has positive effects on energy balance and insulin/glucose levels, suggesting positive effects on aspects of the metabolic syndrome (20), which is so prominent in many psychiatric disorders and may be a key driver of early mortality related to cardiovascular disease (6, 14). Bigio et al. (20) concluded that “agents such as LAC that regulate metabolic factors and reduce glutamate overflow could rapidly ameliorate depression and could also be considered for treatment of insulin resistance in depressed subjects.”

Nasca et al. (1) suggest that low LAC levels may be a state marker of depression since all of their patients were in a depressive episode at the time of study, but one could envision these low levels turning out to be a trait marker of either depression vulnerability or a persisting effect of a person having experienced childhood adversity. Whichever turns out to be the case, the findings of Nasca et al. (1) are clinically impactful and groundbreaking. They also hold the possibility of heralding a new era of biological markers, personalized medicine, and paradigm-shifting acute and preventative treatments at the level of epigenetics.

Footnotes

  • ↵1Email: robert.post{at}speakeasy.net.
  • Author contributions: R.M.P. wrote the paper.

  • The author declares no conflict of interest.

  • See companion article on page 8627.

Published under the PNAS license.

View Abstract

References

  1. ↵
    1. Nasca C, et al.
    (2018) Acetyl-l-carnitine deficiency in patients with major depressive disorder. Proc Natl Acad Sci USA 115:8627–8632.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Nasca C, et al.
    (2013) l-Acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci USA 110:4804–4809.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Post RM, et al.
    (2017) More childhood onset bipolar disorder in the United States than Canada or Europe: Implications for treatment and prevention. Neurosci Biobehav Rev 74:204–213.
    OpenUrl
  4. ↵
    1. Bersani G, et al.
    (2013) l-Acetylcarnitine in dysthymic disorder in elderly patients: A double-blind, multicenter, controlled randomized study vs. fluoxetine. Eur Neuropsychopharmacol 23:1219–1225.
    OpenUrl
  5. ↵
    1. Post R,
    2. Leverich G
    (2008) Treatment of Bipolar Illness: A Casebook for Clinicians and Patients (Norton, New York).
  6. ↵
    1. Strain J,
    2. Blumenfeld M
    1. Post R
    (2016) Depression as a recurrent, progressive illness: Need for long-term prevention. Depression as a Systemic Disease, eds Strain J, Blumenfeld M (Oxford Univ Press, Oxford).
  7. ↵
    1. Post RM,
    2. Kalivas P
    (2013) Bipolar disorder and substance misuse: Pathological and therapeutic implications of their comorbidity and cross-sensitisation. Br J Psychiatry 202:172–176.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Berk M, et al.
    (2008) N-acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial. Biol Psychiatry 64:468–475.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Nasca C, et al.
    (2017) Role of the astroglial glutamate exchanger xCT in ventral hippocampus in resilience to stress. Neuron 96:402–413.e5.
    OpenUrl
  10. ↵
    1. Danese A,
    2. Baldwin JR
    (2017) Hidden wounds? Inflammatory links between childhood trauma and psychopathology. Annu Rev Psychol 68:517–544.
    OpenUrl
  11. ↵
    1. Shonkoff JP,
    2. Garner AS, Committee on Psychosocial Aspects of Child and Family Health; Committee on Early Childhood, Adoption, and Dependent Care; Section on Developmental and Behavioral Pediatrics
    (2012) The lifelong effects of early childhood adversity and toxic stress. Pediatrics 129:e232–e246.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Post RM
    (1992) Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 149:999–1010.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Post RM
    (2016) Epigenetic basis of sensitization to stress, affective episodes, and stimulants: Implications for illness progression and prevention. Bipolar Disord 18:315–324.
    OpenUrl
  14. ↵
    1. Stoddard FJ,
    2. Benedek DM,
    3. Milad MR,
    4. Ursano RJ
    1. Post RM
    (2018) The neurochemistry and epigenetics of PTSD: Implications for therapeutics in trauma- and stressor-related disorders. Trauma- and Stressor-Related Disorders, eds Stoddard FJ, Benedek DM, Milad MR, Ursano RJ (Oxford Univ Press, New York), pp 161–176.
  15. ↵
    1. Kessing LV,
    2. Mortensen PB,
    3. Bolwig TG
    (1998) Clinical definitions of sensitisation in affective disorder: A case register study of prevalence and prediction. J Affect Disord 47:31–39.
    OpenUrlPubMed
  16. ↵
    1. Post RM
    (2018) Preventing the malignant transformation of bipolar disorder. JAMA 319:1197–1198.
    OpenUrl
  17. ↵
    1. Tsankova NM, et al.
    (2006) Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 9:519–525.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Krishnan V, et al.
    (2007) Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 131:391–404.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Lau T,
    2. Bigio B,
    3. Zelli D,
    4. McEwen BS,
    5. Nasca C
    (2017) Stress-induced structural plasticity of medial amygdala stellate neurons and rapid prevention by a candidate antidepressant. Mol Psychiatry 22:227–234.
    OpenUrl
  20. ↵
    1. Bigio B, et al.
    (2016) Epigenetics and energetics in ventral hippocampus mediate rapid antidepressant action: Implications for treatment resistance. Proc Natl Acad Sci USA 113:7906–7911.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Article Alerts
Email Article

Thank you for your interest in spreading the word on PNAS.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Myriad of implications of acetyl-l-carnitine deficits in depression
(Your Name) has sent you a message from PNAS
(Your Name) thought you would like to see the PNAS web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Myriad of implications of acetyl-l-carnitine deficits in depression
Robert M. Post
Proceedings of the National Academy of Sciences Aug 2018, 115 (34) 8475-8477; DOI: 10.1073/pnas.1811389115

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Myriad of implications of acetyl-l-carnitine deficits in depression
Robert M. Post
Proceedings of the National Academy of Sciences Aug 2018, 115 (34) 8475-8477; DOI: 10.1073/pnas.1811389115
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Mendeley logo Mendeley
Proceedings of the National Academy of Sciences: 115 (34)
Table of Contents

Submit

Sign up for Article Alerts

Article Classifications

  • Biological Sciences
  • Medical Sciences

Jump to section

  • Article
    • Footnotes
    • References
  • Figures & SI
  • Info & Metrics
  • PDF

You May Also be Interested in

Abstract depiction of a guitar and musical note
Science & Culture: At the nexus of music and medicine, some see disease treatments
Although the evidence is still limited, a growing body of research suggests music may have beneficial effects for diseases such as Parkinson’s.
Image credit: Shutterstock/agsandrew.
Large piece of gold
News Feature: Tracing gold's cosmic origins
Astronomers thought they’d finally figured out where gold and other heavy elements in the universe came from. In light of recent results, they’re not so sure.
Image credit: Science Source/Tom McHugh.
Dancers in red dresses
Journal Club: Friends appear to share patterns of brain activity
Researchers are still trying to understand what causes this strong correlation between neural and social networks.
Image credit: Shutterstock/Yeongsik Im.
Yellow emoticons
Learning the language of facial expressions
Aleix Martinez explains why facial expressions often are not accurate indicators of emotion.
Listen
Past PodcastsSubscribe
Goats standing in a pin
Transplantation of sperm-producing stem cells
CRISPR-Cas9 gene editing can improve the effectiveness of spermatogonial stem cell transplantation in mice and livestock, a study finds.
Image credit: Jon M. Oatley.

Similar Articles

Site Logo
Powered by HighWire
  • Submit Manuscript
  • Twitter
  • Facebook
  • RSS Feeds
  • Email Alerts

Articles

  • Current Issue
  • Special Feature Articles – Most Recent
  • List of Issues

PNAS Portals

  • Anthropology
  • Chemistry
  • Classics
  • Front Matter
  • Physics
  • Sustainability Science
  • Teaching Resources

Information

  • Authors
  • Editorial Board
  • Reviewers
  • Librarians
  • Press
  • Site Map
  • PNAS Updates

Feedback    Privacy/Legal

Copyright © 2021 National Academy of Sciences. Online ISSN 1091-6490